Technology
Health
Biotechnology

Bellicum Pharmaceuticals

$3.66
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.03 (-0.81%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell BLCM and other stocks, options, ETFs, and crypto commission-free!

About

Bellicum Pharmaceuticals, Inc. Common Stock, also called Bellicum Pharmaceuticals, is a clinical stage biopharmaceutical company, which focuses on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. Read More It uses its proprietary chemical induction of dimerization that controls components of the immune system in real time. The company was founded by Kevin M. Slawin and David M. Spencer on July 14, 2004 and is headquartered in Houston, TX.

Employees
173
Headquarters
Houston, Texas
Founded
2004
Market Cap
159.45M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
579.00K
High Today
$3.86
Low Today
$3.65
Open Price
$3.71
Volume
309.42K
52 Week High
$10.26
52 Week Low
$2.74

Collections

Technology
Health
Biotechnology
Medical
Biopharmaceutical
Pharmaceutical
2014 IPO
US

News

Seeking AlphaMar 13

Bellicum Pharmaceuticals, Inc.'s (BLCM) CEO Rick Fair on Q4 2018 Results - Earnings Call Transcript

Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) Q4 2018 Results Earnings Conference Call March 12, 2019 5:00 PM ET Company Participants Atabak Mokari - Chief Financial Officer Rick Fair - President and CEO Bill Grossman - Chief Medical Officer Aaron Foster - Head, Research Conference Call Participants Biren Amin - Jeffries Jim Birchenough - Wells Fargo Securities Wangzhi Li - Ladenberg Peter Lawson - SunTrust Robinson Humphrey Reni Benjamin - Raymond James Operator Ladies and gentlemen, greetings....

128
BenzingaMar 12

Bellicum Pharmaceuticals (NASDAQ:BLCM) - Bellicum Pharmaceuticals Q4 Earnings Preview

Bellicum Pharmaceuticals, Inc. - Common Stock (NASDAQ: BLCM) announces its next round of earnings this Tuesday, March 12. Here's Benzinga's advanced look at Bellicum's Q4 earnings report. Earnings and Revenue Bellicum EPS is expected to be around a loss of 56 cents per share, according to sell-side analysts. Sales will likely be near $1.19 million. In the same quarter last year, Bellicum announced EPS loss of 61 cents. Bellicum's reported EPS has stacked up against analyst estimates in the past like this...

196
Simply Wall StFeb 28

Does Market Volatility Impact Bellicum Pharmaceuticals, Inc.’s (NASDAQ:BLCM) Share Price?

Anyone researching Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) might want to consider the historical volatility of the share price. Volatility is considered to be a measure of risk in modern finance theory. Investors may think of volatility as falling into two main categories. The first type is company specific volatility. Investors use diversification across uncorrelated stocks to reduce this kind of price volatility across the portfolio. The other type, which cannot be diversified away, is the volatility...

98

Earnings

-$0.74
-$0.68
-$0.61
-$0.55
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
-$0.56 per share
Actual
-$0.63 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.